Collection of biological samples from patients with autoimmune skin diseases
Constitution of a Collection of Biological Samples With the Aim of Carrying Out Clinico-biological and Physiopathological Investigations of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases
This study is collecting blood and other samples from people with autoimmune skin diseases to see if it can find new ways to diagnose and treat these conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 6 Years to 99 Years |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT06387654 on ClinicalTrials.gov |
What this trial studies
This project aims to create a comprehensive collection of biological and clinical data from patients suffering from autoimmune, dysimmune, or auto-inflammatory dermatological diseases. By gathering blood samples and other biological materials, the study seeks to identify new biomarkers that could lead to innovative therapeutic strategies. The research focuses on understanding the complex mechanisms behind these diseases, which affect a significant portion of the adult population, particularly women. The findings will be made accessible to the medical and scientific communities to enhance diagnostic and treatment options.
Who should consider this trial
Good fit: Ideal candidates include adults and children with documented autoimmune, dysimmune, or auto-inflammatory skin conditions.
Not a fit: Patients under protective supervision, those under 6 years old, and pregnant or breastfeeding women may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the identification of new biomarkers and therapeutic strategies for patients with autoimmune skin diseases.
How similar studies have performed: Other studies have shown success in identifying biomarkers for autoimmune diseases, suggesting a promising approach in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Skin damage of documented or probable autoimmune, dysimmune or autoinflammatory origin. The patients included may be adults or children, and will be: * Patients with autoimmune bullous dermatoses (pemphigus, pemphigoid and others), * Patients with systemic autoimmune diseases associated with skin damage (lupus, scleroderma, dermatomyositis for example), * Patients with cutaneous lupus * Patients with dysimmune skin diseases (psoriasis, eczema) * Patients with immuno-induced dermatological disorders or drug dermatitis * Patients receiving, or likely to receive, new, innovative therapies (new molecule on the market, checkpoint inhibitors, gene therapy, cell therapy, etc.). Patients with dermatological damage whose autoimmune, dysimmune or auto-inflammatory origin is suspected Exclusion Criteria: * Patients under protective supervision (guardianship, curators) * Patients under 6 years old * Pregnant or breastfeeding woman
Where this trial is running
Toulouse
- University Hospital — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Chloé BOST, MD, PhD — University Hospital, Toulouse
- Study coordinator: Chloé BOST, MD, PhD
- Email: bost.c@chu-toulouse.fr
- Phone: 5 61 77 61 44
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.